The impact of shift duration on the efficacy and tolerability of armodafinil in patients with excessive sleepiness associated with shift work disorder

Of the 383 patients enrolled, 279 (73%) worked shifts ≤9 hours and 104 (27%) worked shifts >9 hours.

• Patients receiving armodafinil showed at least minimal improvement in late-in-shift clinical condition compared to those receiving a placebo.
• In patients working shifts ≤9 hours, 78% of those on armodafinil experienced improvement in late-in-shift Clinical Global Impressions-Change rating, versus 60% for placebo (P = 0.0017).
• For patients working shifts >9 hours, 77% on armodafinil reported improvement compared to 46% on placebo (P = 0.0020).
• Armodafinil treatment led to significantly greater improvements in Global Assessment of Functioning scores in both shift duration groups.
• Headache was the most frequent adverse event reported across all treatment groups.

AI simplified